24 80

Cited 0 times in

Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study

DC Field Value Language
dc.contributor.author이용재-
dc.contributor.author이정윤-
dc.date.accessioned2022-08-19T06:26:04Z-
dc.date.available2022-08-19T06:26:04Z-
dc.date.issued2019-11-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/189168-
dc.description.abstractBackground: Olaparib maintenance therapy has shown efficacy and tolerability in patients with platinum-sensitive, high-grade serous recurrent ovarian cancer (HSROC) with BRCA1/2 mutation (BRCAm). Our aim was to present real-world experience with olaparib in Korea. Method: We included HSROC patients with BRCAm treated with olaparib maintenance at four institutions in Korea between 2016 and 2018. Medical records were reviewed for clinico-pathologic characteristics, objective response, survival outcomes, and safety. Results: One hundred HSROC patients with BRCAm were included. BRCA1 mutation was present in 71 patients (71.0%), and BRCA2 mutation was present in 23 patients (23.0%). In terms of the best objective response with olaparib maintenance in 53 patients with partial remission from most recent chemotherapy, complete remission occurred in 12 (22.6%) and partial remission in four (7.5%), while 33 patients (62.3%) had stable disease. The 24 month progression-free survival was 42.4%, and 24 month overall survival was 82.1%. Grade 3 or more adverse events were as follows: anemia in 14 patients (14.0%), neutropenia in seven patients (7.0%), thrombocytopenia in two patients (2.0%), oral mucositis in one patient (1.0%), and soft tissue infection in one patient (1.0%). Conclusions: The safety and effectiveness of olaparib maintenance treatment in a real-world study were consistent with those reported in previous clinical trials.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherMDPI AG-
dc.relation.isPartOfJOURNAL OF CLINICAL MEDICINE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleReal-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Obstetrics and Gynecology (산부인과학교실)-
dc.contributor.googleauthorE Sun Paik-
dc.contributor.googleauthorYong Jae Lee-
dc.contributor.googleauthorJung-Yun Lee-
dc.contributor.googleauthorWonkyo Shin-
dc.contributor.googleauthorSang-Yoon Park-
dc.contributor.googleauthorSe Ik Kim-
dc.contributor.googleauthorJae-Weon Kim-
dc.contributor.googleauthorChel Hun Choi-
dc.contributor.googleauthorByoung-Gie Kim-
dc.identifier.doi10.3390/jcm8111920-
dc.contributor.localIdA05165-
dc.contributor.localIdA04638-
dc.relation.journalcodeJ03556-
dc.identifier.eissn2077-0383-
dc.identifier.pmid31717415-
dc.subject.keywordolaparib-
dc.subject.keywordrecurrent ovarian epithelial carcinoma-
dc.subject.keywordmaintenance therapy-
dc.subject.keywordtreatment efficacy-
dc.subject.keywordadverse effects-
dc.contributor.alternativeNameLee, Yong Jae-
dc.contributor.affiliatedAuthor이용재-
dc.contributor.affiliatedAuthor이정윤-
dc.citation.volume8-
dc.citation.number11-
dc.citation.startPage1920-
dc.identifier.bibliographicCitationJOURNAL OF CLINICAL MEDICINE, Vol.8(11) : 1920, 2019-11-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Obstetrics and Gynecology (산부인과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.